With each new drug discovery, Gilead seeks to improve the care of millions of patients living with life-threatening diseases around the world.
Gilead recognises that patients and communities often face challenges in accessing the best possible care, and we know that passion for scientific discovery alone — and that Gilead alone — cannot solve these challenges. This is why, through our grant programs in Australia and New Zealand, Gilead supports patient advocacy organisations, healthcare professionals and nonprofit groups that work tirelessly in local communities to improve people’s lives day after day.
Gilead provides a range of funding opportunities for innovative and inspiring projects in Australia and New Zealand, which improve health access, eliminate barriers to healthcare, advance education for healthcare professionals and support local communities.
Gilead believes medicines should be accessible to all people who need them, regardless of where they live or what resources they have. Political, social and geographical barriers prevent people around the world from accessing the best possible care. We work with partners and grantees to help overcome those barriers.
At Gilead Australia and New Zealand, we fund projects that support underserved communities that have systematically experienced greater social or economic obstacles to health.
Advancing Medical Education
Gilead Australia and New Zealand recognises that education is key to effective disease prevention and long-term disease management. Gilead helps community organisations by supporting disease awareness programs for patients and expanding knowledge and skills for healthcare professionals.
Supporting Local Communities
With more than 18,000 employees working in over 35 countries around the world, Gilead understands how important it is for people of all backgrounds to live in vibrant local communities. Gilead Australia and New Zealand funds initiatives that promote the well-being and improvement of the local neighborhoods and cities in which we live and work.